Pew Offers Comments on Increasing Price Transparency for Prescription Drugs in Oregon

Approach could lower drug costs for the state

Pew Offers Comments on Increasing Price Transparency for Prescription Drugs in Oregon

On Sept. 25, The Pew Charitable Trusts’ drug spending research initiative submitted comments to Oregon’s Joint Task Interim Force on Fair Pricing of Prescription Drugs on how increasing the transparency of drug prices could help lower costs to the state.

Pew’s comments summarize a policy option that could help Oregon’s Medicaid program secure larger drug rebates and avoid overpaying for medications by requiring drug manufacturers to confidentially report discounts provided to pharmacy benefit managers and other negotiating entities.  

America’s Overdose Crisis
America’s Overdose Crisis

America’s Overdose Crisis

Sign up for our five-email course explaining the overdose crisis in America, the state of treatment access, and ways to improve care

Sign up
Quick View

America’s Overdose Crisis

Sign up for our five-email course explaining the overdose crisis in America, the state of treatment access, and ways to improve care

Sign up